{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:10Z","timestamp":1794047410556,"version":"4.8.0"},"reference-count":34,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The optimum management approach for patients with relapsed or refractory follicular lymphoma remains uncertain. Autologous stem cell transplantation (autoSCT) is considered a standard option in suitable, younger patients with relapsed follicular lymphoma. AutoSCT is associated with very durable remissions in a minority of subjects, but also with significant, well-established toxicities. Although positron emission tomography (PET) status prior to autoSCT is an established prognostic factor in diffuse large B-cell lymphoma and Hodgkin lymphoma, no data exist in follicular lymphoma. We describe survival outcomes according to pre-transplant PET status, classified by the Lugano criteria into complete metabolic remission (CMR) versus non-CMR, in 172 patients with relapsed or refractory follicular lymphoma within a national, multicenter, retrospective British Society of Blood and Marrow Transplantation and Cellular Therapy registry study. The median number of lines of therapy prior to SCT was three (range, 1-6). The median follow-up after SCT was 27 months (range, 3\u201370). The median progression-free survival for all patients after autoSCT was 28 months (interquartile range, 23- 36). There was no interaction between age at transplantation, sex, number of months since last relapse, Karnofsky performance status or comorbidity index and achieving CMR prior to autoSCT. Superior progression-free survival was observed in 115 (67%) patients obtaining CMR versus 57 (33%) non-CMR patients (3-year progression-free survival 50% vs. 22%, P=0.011) and by pre-SCT Deauville score (continuous variable 1-5, hazard ratio [HR]=1.32, P=0.049). PET status was independently associated with progression-free status (non-CMR HR=2.02, P=0.003), overall survival (non-CMR HR=3.08, P=0.010) and risk of relapse (non-CMR HR=1.64, P=0.046) after autoSCT by multivariable analysis. Our data suggest that pre- SCT PET status is of clear prognostic value and may help to improve the selection of patients for autoSCT.<\/jats:p>","DOI":"10.3324\/haematol.2021.280287","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T03:45:24Z","timestamp":1652931924000},"page":"785-796","source":"Crossref","is-referenced-by-count":6,"title":["Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation"],"prefix":"10.3324","volume":"108","author":[{"given":"Toby A.","family":"Eyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally F.","family":"Barrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Okosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"Abamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.C.","family":"Bloor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gilleece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimish","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Malladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"45532","doi-asserted-by":"crossref","unstructured":"Link BK, Day B, Zhou X. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational national LymphoCare study. Br J Haematol. 2019; 184(4):660-663.","DOI":"10.1111\/bjh.15149"},{"key":"45533","doi-asserted-by":"crossref","unstructured":"McNamara C, Montoto S, Eyre TA. The investigation and management of follicular lymphoma. Br J Haematol. 2020; 191(3):363-381.","DOI":"10.1111\/bjh.16872"},{"key":"45534","doi-asserted-by":"crossref","unstructured":"Casulo C, Friedberg JW, Ahn KW. Autologous transplantation in follicular lymphoma with early therapy failure: a national LymphoCare study and Center for International Blood and Marrow Transplant Research analysis. Biol. Blood Marrow Transplant. 2018; 24(6):1163-1171.","DOI":"10.1016\/j.bbmt.2017.12.771"},{"key":"45535","doi-asserted-by":"crossref","unstructured":"Smith SM, Godfrey J, Ahn KW. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018; 124(12):2541-2551.","DOI":"10.1002\/cncr.31374"},{"key":"45536","doi-asserted-by":"crossref","unstructured":"Robinson SP, Canals C, Luang JJ. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant. 2013; 48(11):1409-1414.","DOI":"10.1038\/bmt.2013.83"},{"key":"45537","doi-asserted-by":"crossref","unstructured":"Vose JM, Bierman PJ, Loberiza FR. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant. 2008; 14(1):36-42.","DOI":"10.1016\/j.bbmt.2007.06.016"},{"key":"45538","doi-asserted-by":"crossref","unstructured":"Montoto S, Canals C, Rohatiner AZS. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007; 21(11):2324-2331.","DOI":"10.1038\/sj.leu.2404850"},{"key":"45539","doi-asserted-by":"crossref","unstructured":"Rohatiner AZS, Nadler L, Davies AJ. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007; 25(18):2554-2559.","DOI":"10.1200\/JCO.2006.09.8327"},{"key":"45540","doi-asserted-by":"crossref","unstructured":"Evens AM, Vanderplas A, Lacasce AS. Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013; 119(20):3662-3671.","DOI":"10.1002\/cncr.28243"},{"key":"45541","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Ubieto A, Grande C, Caballero D. Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure. Biol Blood Marrow Transplant. 2017; 23(10):1631-1640.","DOI":"10.1016\/j.bbmt.2017.05.021"},{"key":"45542","doi-asserted-by":"crossref","unstructured":"Jurinovic V, Metzner B, Pfreundschuh M. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant. 2018; 24(6):1172-1179.","DOI":"10.1016\/j.bbmt.2018.03.022"},{"key":"45543","doi-asserted-by":"crossref","unstructured":"Meignan M, Cottereau AS, Versari A. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016; 34(30):3618-3626.","DOI":"10.1200\/JCO.2016.66.9440"},{"key":"45544","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"45545","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014; 32(27):3048-3058.","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"45546","doi-asserted-by":"crossref","unstructured":"Trotman J, Fournier M, Lamy T. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011; 29(23):3194-3200.","DOI":"10.1200\/JCO.2011.35.0736"},{"key":"45547","doi-asserted-by":"crossref","unstructured":"Trotman J, Barrington SF, Belada D. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018; 19(11):1530-1542.","DOI":"10.1016\/S1470-2045(18)30618-1"},{"key":"45548","doi-asserted-by":"crossref","unstructured":"Trotman J, Luminari S, Boussetta S. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014; 1(1):e17-e27.","DOI":"10.1016\/S2352-3026(14)70008-0"},{"key":"45549","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010; 116(23):4934-4937.","DOI":"10.1182\/blood-2010-05-282756"},{"key":"45550","doi-asserted-by":"crossref","unstructured":"Sauter CS, Matasar MJ, Meikle J. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015; 125(16):2579-2581.","DOI":"10.1182\/blood-2014-10-606939"},{"key":"45551","doi-asserted-by":"crossref","unstructured":"Svoboda J, Andreadis C, Elstrom R. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2006; 38(3):211-216.","DOI":"10.1038\/sj.bmt.1705416"},{"key":"45552","doi-asserted-by":"crossref","unstructured":"Van Imhoff GW, McMillan A, Matasar MJ. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017; 35(5):544-551.","DOI":"10.1200\/JCO.2016.69.0198"},{"key":"45553","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"45554","doi-asserted-by":"crossref","unstructured":"Cox DR. Models and life-tables regression. J R Stat Soc. 1972; 34(2):187-202.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"45555","doi-asserted-by":"crossref","unstructured":"Kelsey P, Pearce R, Perry J. Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory lymphoma - a retrospective study from the BSBMT (BEAM versus LEAM). Bone Marrow Transplant. 2021; 56:730-732.","DOI":"10.1038\/s41409-020-01071-2"},{"key":"45556","doi-asserted-by":"crossref","unstructured":"Thomson KJ, Morris EC, Milligan D. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010; 28(23):3695-3700.","DOI":"10.1200\/JCO.2009.26.9100"},{"key":"45557","doi-asserted-by":"crossref","unstructured":"Leonard JP, Trneny M, Izutsu K. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019; 37(14):1188-1199.","DOI":"10.1200\/JCO.19.00010"},{"key":"45558","doi-asserted-by":"crossref","unstructured":"Gopal AK, Kahl BS, de Vos S. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370(11):1008-1018.","DOI":"10.1056\/NEJMoa1314583"},{"key":"45559","doi-asserted-by":"crossref","unstructured":"Flinn IW, Miller CB, Ardeshna KM. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2019; 37(11):912-922.","DOI":"10.1200\/JCO.18.00915"},{"key":"45560","doi-asserted-by":"crossref","unstructured":"Caimi P, Kahl BS, Hamadani M. Safety and efficacy of Adct-402 (loncastuximab tesirine), a novel antibody drug conjugate, in relapsed\/refractory follicular lymphoma and mantle cell lymphoma: interim results from the phase 1 first-in-human study. Blood. 2018; 132(Suppl 1):2874.","DOI":"10.1182\/blood-2018-99-118133"},{"key":"45561","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Tilly H, Chaidos A. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020; 21(11):1433-1442.","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"45562","doi-asserted-by":"crossref","unstructured":"Budde LE, Assouline S, Sehn LH. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022; 40(5):481-491.","DOI":"10.1200\/JCO.21.00931"},{"key":"45563","doi-asserted-by":"crossref","unstructured":"Hutchings M, Morschhauser F, Iacoboni G. Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021; 39(18):1959-1970.","DOI":"10.1200\/JCO.20.03175"},{"key":"45564","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Dickinson MJ, Dreyling MH. Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed\/refractory follicular lymphoma (r\/r FL): primary analysis of the phase 2 ELARA trial. J Clin Oncol. 2021; 39(15 Suppl):7508.","DOI":"10.1200\/JCO.2021.39.15_suppl.7508"},{"key":"45565","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Chavez JC, Sehgal AR. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022; 23(1):91-103.","DOI":"10.1016\/S1470-2045(21)00591-X"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280287\/74468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280287\/75384","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10648\/74468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:42Z","timestamp":1794045702000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.280287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.280287","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,19]]}}}